Arbejdsmarkedets Tillaegspension Grows Position in Qiagen N.V. $QGEN

Arbejdsmarkedets Tillaegspension grew its holdings in Qiagen N.V. (NYSE:QGEN) by 24.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 636,918 shares of the company’s stock after buying an additional 126,405 shares during the period. Arbejdsmarkedets Tillaegspension’s holdings in Qiagen were worth $25,502,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of QGEN. Boston Partners purchased a new stake in Qiagen during the 3rd quarter valued at about $179,450,000. Norges Bank purchased a new position in Qiagen during the fourth quarter worth approximately $166,500,000. Dimensional Fund Advisors LP acquired a new position in shares of Qiagen during the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD increased its position in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Up 0.0%

Qiagen stock opened at $41.52 on Monday. The firm has a market capitalization of $8.56 billion, a P/E ratio of 21.68, a P/E/G ratio of 4.14 and a beta of 0.64. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The stock’s fifty day simple moving average is $36.59 and its 200-day simple moving average is $42.56.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.54. The firm had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period last year, the business posted $0.56 earnings per share. As a group, equities analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be paid a $0.35 dividend. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s payout ratio is 18.32%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on QGEN. TD Cowen reissued a “hold” rating and issued a $40.00 price target (down from $46.00) on shares of Qiagen in a research note on Thursday, May 7th. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Stifel Nicolaus set a $36.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a research report on Monday, May 18th. Zacks Research raised Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the company a “hold” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $43.15.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.